Antibody–drug conjugates (ADCs) are promising targeted cancer therapies but have a limited payload scope. Antibody–bottlebrush prodrug conjugates offer modular synthesis and high drug-to-antibody ratios, enabling the use of a broad range of payloads, including lower potency drugs, while performing favorably compared to traditional ADCs in preclinical models.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641–661 (2023). A review article that presents the therapeutic potential of ADCs in cancer treatment.
Mckertish, C. M. & Kayser, V. Advances and limitations of antibody drug conjugates for cancer. Biomedicines 9, 872 (2021). A review article that presents both the therapeutic promise and the current limitations of ADCs in cancer therapy.
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y. & Agatsuma, T. The Latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem. Pharm. Bull. 67, 173–185 (2019). A review article that presents recent research on the ADC trastuzumab deruxtecan, including insights into payload potency requirements for effective ADC design.
Johnson, J. A. et al. Core-clickable PEG-branch-azide bivalent-bottle-brush polymers by ROMP: grafting-through and clicking-to. J. Am. Chem. Soc. 133, 559–566 (2011). This paper reports the rational design and synthesis of BPDs.
Liu, B. et al. An organometallic swap strategy for bottlebrush polymer–protein conjugate synthesis. Chem. Commun. 60, 4238–4241 (2024). This paper reports terminal functionalization of BPDs with clickable groups for bioconjugation.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Liu, B. et al. Antibody–bottlebrush prodrug conjugates for targeted cancer therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02772-z (2025).
Rights and permissions
About this article
Cite this article
Antibody–bottlebrush prodrugs pack a punch for targeted cancer therapy. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02773-y
Published:
DOI: https://doi.org/10.1038/s41587-025-02773-y
